Etiology and Factors Affecting Severe Complications and Mortality of Febrile Neutropenia in Children with Acute Leukemia

Objective: Febrile neutropenia (FN) is an important complication that causes high rates of morbidity and mortality in patients with malignancies. We aimed to investigate the etiology, epidemiological distribution and its change over the years, clinical courses, and outcomes of FN in children with acute leukemia. Materials and Methods: We retrospectively analyzed the demographic data, clinical characteristics, laboratory results, severe complications, and mortality rates of pediatric patients with FN between January 2010 and December 2020. Results: In 153 patients, a total of 450 FN episodes (FNEs) occurred. Eighty-four (54.9%) of these patients were male, the median age of the patients was 6.5 (range: 3-12.2) years, and 127 patients (83%) were diagnosed with acute lymphoblastic leukemia. Fever with a focus was found in approximately half of the patients, and an etiology was identified for 38.7% of the patients. The most common fever focus was bloodstream infection (n=74, 16.5%). Etiologically, a bacterial infection was identified in 22.7% (n=102), a viral infection in 13.3% (n=60), and a fungal infection in 5.8% (n=26) of the episodes. Twenty-six (23.2%) of a total of 112 bacteria were multidrug resistant (MDR) The rate of severe complications was 7.8% (n=35) and the mortality rate was 2% (n=9). In logistic regression analysis, refractory/relapsed malignancies and high C-reactive protein (CRP) at first admission were found to be the most important independent risk factors for mortality. Prolonged neutropenia after chemotherapy, diagnosis of acute myeloid leukemia, identification of fever focus or etiological agents, invasive fungal infections, polymicrobial infections, and need for intravenous immunoglobulin treatment increased the frequency of severe complications. Conclusion: We found that there was no significant change in the epidemiological distribution or frequency of resistant bacteria in our center in the last 10 years compared to previous years. Prolonged duration of fever, relapsed/refractory malignancies, presence of fever focus, and high CRP level were significant risk factors for poor clinical course and outcome.

[1]  A. Groll,et al.  8th European Conference on Infections in Leukaemia: 2020 guidelines for the use of antibiotics in paediatric patients with cancer or post-haematopoietic cell transplantation. , 2021, The Lancet. Oncology.

[2]  R. Seth,et al.  Outcomes of Febrile Neutropenia in Children With Cancer Managed on an Outpatient Basis: A Report From Tertiary Care Hospital From a Resource-limited Setting , 2020, Journal of pediatric hematology/oncology.

[3]  M. Bhatia,et al.  Microbiological Profile of Blood Stream Infections in Febrile Neutropenic Patients at a Tertiary Care Teaching Hospital in Rishikesh, Uttarakhand , 2020, Journal of Laboratory Physicians.

[4]  G. Gabutti,et al.  Viral Respiratory Infections in Hematological Patients , 2020, Infectious Diseases and Therapy.

[5]  A. Simon,et al.  Management of children with fever and neutropenia: results of a survey in 51 pediatric cancer centers in Germany, Austria, and Switzerland , 2020, Infection.

[6]  Han Xiao,et al.  Risk Prediction and Prognosis of Invasive Fungal Disease in Hematological Malignancies Patients Complicated with Bloodstream Infections , 2020, Cancer management and research.

[7]  S. Kabra,et al.  Prevalence and clinical outcome of respiratory viral infections among children with cancer and febrile neutropenia , 2019, Pediatric hematology and oncology.

[8]  R. Dessein,et al.  Differential risk of severe infection in febrile neutropenia among children with blood cancer or solid tumor. , 2019, The Journal of infection.

[9]  K. Yu,et al.  Clinical risk score for invasive fungal diseases in patients with hematological malignancies undergoing chemotherapy: China Assessment of Antifungal Therapy in Hematological Diseases (CAESAR) study , 2019, Frontiers of Medicine.

[10]  Hande Kızılocak,et al.  Febrile Neutropenia in Children with Cancer: Approach to Diagnosis and Treatment. , 2018, Current pediatric reviews.

[11]  A. Trehan,et al.  Risk Factors for Microbiologically-documented Infections, Mortality and Prolonged Hospital Stay in Children with Febrile Neutropenia , 2018, Indian Pediatrics.

[12]  R. Ammann,et al.  Pediatric patients at risk for fever in chemotherapy-induced neutropenia in Bern, Switzerland, 1993-2012 , 2018, Scientific Data.

[13]  Jae Wook Lee,et al.  Clinical characteristics and outcomes of Pseudomonas aeruginosa bacteremia in febrile neutropenic children and adolescents with the impact of antibiotic resistance: a retrospective study , 2017, BMC Infectious Diseases.

[14]  A. Trehan,et al.  Can complications in febrile neutropenia be predicted? Report from a developing country , 2017, Supportive Care in Cancer.

[15]  S. Alexander,et al.  Guideline for the Management of Fever and Neutropenia in Children With Cancer and Hematopoietic Stem-Cell Transplantation Recipients: 2017 Update. , 2017, Journal of clinical oncology : official journal of the American Society of Clinical Oncology.

[16]  Jae Wook Lee,et al.  Increase in Antibiotic-Resistant Gram-Negative Bacterial Infections in Febrile Neutropenic Children , 2016, Infection & chemotherapy.

[17]  J. Albert,et al.  Frequent Respiratory Viral Infections in Children with Febrile Neutropenia - A Prospective Follow-Up Study , 2016, PloS one.

[18]  He Huang,et al.  Epidemiology, management, and outcome of invasive fungal disease in patients undergoing hematopoietic stem cell transplantation in China: a multicenter prospective observational study. , 2015, Biology of blood and marrow transplantation : journal of the American Society for Blood and Marrow Transplantation.

[19]  J. Carratalá,et al.  Bloodstream infections in neutropenic patients with cancer: differences between patients with haematological malignancies and solid tumours. , 2014, Journal of Infection.

[20]  C. Viscoli,et al.  Prophylaxis and Empirical Therapy of Infection in Cancer Patients , 2014, Mandell, Douglas, and Bennett's Principles and Practice of Infectious Diseases.

[21]  E. Trecarichi,et al.  Antimicrobial-resistant Gram-negative bacteria in febrile neutropenic patients with cancer: current epidemiology and clinical impact , 2014, Current opinion in infectious diseases.

[22]  F. Shann,et al.  Antibiotic-resistant Gram-negative Bacteremia in Pediatric Oncology Patients—Risk Factors and Outcomes , 2013, The Pediatric infectious disease journal.

[23]  A. Srinivasan,et al.  Prospective Detection of Respiratory Pathogens in Symptomatic Children With Cancer , 2012, The Pediatric infectious disease journal.

[24]  S. Alexander,et al.  Updated Systematic Review and Meta-Analysis of the Performance of Risk Prediction Rules in Children and Young People with Febrile Neutropenia , 2012, PloS one.

[25]  M. Kim,et al.  Risk factors for and clinical implications of mixed Candida/bacterial bloodstream infections , 2012, Clinical microbiology and infection : the official publication of the European Society of Clinical Microbiology and Infectious Diseases.

[26]  M. Kvezereli-Kopadze,et al.  [Neutropenia in children]. , 2011, Georgian medical news.

[27]  Clsi Performance Standards for Antimicrobial Susceptibility Testing: Twenty-First Informational Supplement , 2010 .

[28]  J. Corral,et al.  Evaluation of six risk factors for the development of bacteremia in children with cancer and febrile neutropenia. , 2010, Current oncology.

[29]  D. Catchpoole,et al.  Respiratory viruses, a common microbiological finding in neutropenic children with fever , 2010, Journal of Clinical Virology.

[30]  D. Srivastava,et al.  Etiology and Clinical Course of Febrile Neutropenia in Children With Cancer , 2009, Journal of pediatric hematology/oncology.

[31]  O. Ruuskanen,et al.  Respiratory Viral Infections in Children With Leukemia , 2008, The Pediatric infectious disease journal.

[32]  B. Lund,et al.  Febrile neutropenia in children with cancer: A retrospective Norwegian multicentre study of clinical and microbiological outcome , 2008, Scandinavian journal of infectious diseases.

[33]  H. Ören,et al.  ASSESSMENT OF FEBRILE NEUTROPENIA EPISODES IN CHILDREN WITH ACUTE LEUKEMIA TREATED WITH BFM PROTOCOLS , 2008, Pediatric hematology and oncology.

[34]  C. Leone,et al.  Procalcitonin (PCT) and C-reactive Protein (CRP) as severe systemic infection markers in febrile neutropenic adults , 2007, BMC infectious diseases.

[35]  C. Viscoli,et al.  A prospective study on the epidemiology of febrile episodes during chemotherapy-induced neutropenia in children with cancer or after hemopoietic stem cell transplantation. , 2007, Clinical infectious diseases : an official publication of the Infectious Diseases Society of America.

[36]  M. Paesmans,et al.  Bacteraemia in febrile neutropenic cancer patients. , 2007, International journal of antimicrobial agents.

[37]  G. Lyman,et al.  Length of stay and mortality associated with febrile neutropenia among children with cancer. , 2005, Journal of clinical oncology : official journal of the American Society of Clinical Oncology.

[38]  C. Viscoli,et al.  Infections in patients with febrile neutropenia: epidemiology, microbiology, and risk stratification. , 2005, Clinical infectious diseases : an official publication of the Infectious Diseases Society of America.

[39]  H. Ariffin,et al.  SURVEILLANCE STUDY OF BACTERAEMIC EPISODES IN FEBRILE NEUTROPENIC CHILDREN , 2002, International journal of clinical practice.

[40]  M. O'Ryan,et al.  Prospective, multicenter evaluation of risk factors associated with invasive bacterial infection in children with cancer, neutropenia, and fever. , 2001, Journal of clinical oncology : official journal of the American Society of Clinical Oncology.

[41]  L. Elting,et al.  The Multinational Association for Supportive Care in Cancer risk index: A multinational scoring system for identifying low-risk febrile neutropenic cancer patients. , 2000, Journal of clinical oncology : official journal of the American Society of Clinical Oncology.

[42]  C. Mullen,et al.  Early hospital discharge of children with cancer treated for fever and neutropenia: identification and management of the low-risk patient. , 1990, Journal of clinical oncology : official journal of the American Society of Clinical Oncology.

[43]  K. Sepkowitz,et al.  Clinical practice guideline for the use of antimicrobial agents in neutropenic patients with cancer: 2010 Update by the Infectious Diseases Society of America. , 2011, Clinical infectious diseases : an official publication of the Infectious Diseases Society of America.

[44]  F. Marco,et al.  Bacterial and fungal bloodstream isolates from 796 hematopoietic stem cell transplant recipients between 1991 and 2000 , 2004, Annals of Hematology.